A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Jonathan RilingerWinfried V KernDaniel DuerschmiedAlexander SupadyChristoph BodeDawid L StaudacherTobias WengenmayerPublished in: Trials (2020)
The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
Keyphrases
- double blind
- coronavirus disease
- sars cov
- placebo controlled
- clinical trial
- randomized controlled trial
- study protocol
- rheumatoid arthritis
- open label
- phase iii
- phase ii
- early onset
- juvenile idiopathic arthritis
- respiratory syndrome coronavirus
- rheumatoid arthritis patients
- intensive care unit
- systemic lupus erythematosus
- respiratory failure